30 results about "Plague vaccine" patented technology

Techniques from two basic approaches, structure-based immunogen design and phage T4 nanoparticle delivery, are developed to construct new plague vaccines. The NH2-terminal β-strand of F1 of Yersinia pestis is transplanted to the COOH-terminus of F1 of Yersinia pestis and the NH2-terminus sequence flanking the β-strand of F1 of Yersinia pestis is duplicated to eliminate polymerization but to retain the T cell epitopes. The mutated F1 is fused to the V antigen of Yersinia pestis to thereby form a fusion protein F1mut-V mutant, which produces a completely soluble monomer. The fusion protein F1mut-V is then arrayed on phage T4 nanoparticles via a small outer capsid protein, Soc, from a T4 phage or a T4-related phage. Both the soluble and T4 decorated F1mut-V provided approximately 100% protection to mice and rats against pneumonic plague evoked by high doses of Yersinia pestis CO92.

Disclosed herein is a method of inducing an immunological response in a subject which comprises administering an immunogenic amount of a purified fusion protein comprising all or part of F1 antigen of Yersinia pestis fused to the amino terminus of all of V antigen of Yersinia pestis, Yersinia enterocolitica, or Yersinia pseudotuberculosis to the subject.

The invention relates to a strain of strangles streptococcus (also known as streptococcus. equi subsp equi) XZ1 with the preservation number of CGMCC No.7830. The strangles streptococcus strain has the16S rRNA gene sequence shown in the sequence table 1; the strain is isolated from sick horses with strangles and has gram positive bacteria, and cells are spherical and are arranged in pairs or cells are bent chain-shaped, which are in poor growth in ordinary broth and plate; beta type hemolysis happens on a plate with 5% of sheep blood, and a completely transparent hemolytic tape with the width of 3 mm can be formed around small dewdrop-shaped bacterial colonies; facultative anaerobic growth can be realized with the growth temperature from 25 DEG C to 40 DEG C, and the optimum growth temperature is 37 DEG C, and the optimum pH value for growth is between 7.4 and 7.5; glucose is fermented for production of acid, and lactose, mannitol and sorbitol cannot be fermented. The strangles streptococcus strain can be used for preparation of strangles inactivated vaccine, and the prepared strangles inactivated vaccine is good in pertinence, low in cost, safe and good in protection effect.

The invention discloses a plague bacteria protein with cellular immune protection function, an encoding gene and an application. The purpose is to provide the protein and the encoding gene which can stimulate T cell immune reaction during plague bacteria infection and immune processes and can generate cellular immune protection function, as well as the application in the preparation of plague vaccines. The experiments prove that the protein of the invention can stimulate T cell immune reaction during the infection and the immune processes of plague bacteria and can generate immune protection function. The protein or gene of the invention can be taken as an active ingredient for preparing the plague vaccines, and can enhance the immune protection effect and the immune protection region of the existing plague vaccines through mutual immunization or the combined immunization with the existing F1 and LcrV antigen or gene with immune protection function, or the preparation of a recombinant fusion multivalent subunit vaccine or DNA vaccine at the same time. The invention provides a new means for searching the protein of the plague bacteria with cellular immune protection function, which can play the important role in the prevention and the treatment of plague and have broad application prospect.

The invention discloses a yersinia pestis F1Vmut fusion protein purification method. The method includes four steps including bacterial lysis, anion exchange chromatography, hydrophobic interaction chromatography and ultrafiltration. According to a purification process, more than 80mg of antigens in purity higher than 95% can be obtained by consumption of each liter of culture only through two-step column chromatography and stepwise elution, and the antigens are less prone to aggregation and beneficial to product quality control. By adoption of the method, high target protein yield and linearrepeatability are realized, industrial amplification is benefited, and the recombinant antigens excellent in immunogenicity and protectiveness are finally obtained. In addition, by adoption of the method, recombinant F1Vmut large-scale preparation can be realized, and a great foundation is laid for industrialization of recombinant plague vaccines.

A Yersinia pestis virulence regulator TyrR and applications thereof are provided. It is found that virulence of TyrR-deleted Yersinia pestis strains is lowered about 10000 times than virulence of wild strains, lack of the TyrR has no influence on in-vitro growth of the Yersinia pestis, and the TyrR can achieve negative regulation of transcription of five aromatic amino acid metabolism genes comprising aroF-tyrA, aroP, aroL and tyrP, and achieve positive regulation of two acid response genes which are hdeB and hdeD, so that the TyrR is proved to be a Yersinia pestis virulence regulator. In an environment having a pH value of 5.0, the survival rate and a growth speed of a Yersinia pestis TyrR mutant strain are lower than that of a wild strain, thus proving that the acid resistance of a TyrR mutant strain is lowered and that the TyrR regulator is closely related to acid resistance of the Yersinia pestis. Applications of the Yersinia pestis virulence regulator TyrR in preparation of anti-plague vaccines, and applications of the virulence regulator TyrR in preparation of medicines adopting the TyrR as a target are provided.

Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, F1 and V from Yersinia pestis and PA antigen from Bacillus anthracia fused in-frame and retaining structural and functional integrity of all three antigens. Another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed with these three antigens on the capsid surface of the bacteriophage nanoparticles. These bivalent immunogenic compositions are able to elicit robust immune response in a subject administered said the bivalent immunogenic compositions and provide protection to the subject against sequential or simultaneous challenge with both anthrax and plague pathogens.

The invention provides a method for producing RHD (rabbit haemorrhagic disease) virus and vaccine by use of common easy-to-culture cell lines such as RK13, ST, VeroE6, BHK-21, PK-15, IBRS-2 and the like. The method comprises the following steps of: inoculating the RHD virus and adsorbing; adding an incubation agent and performing cell incubation; culturing cells with a cell maintenance medium to obtain RHD virus seeds for production; inoculating the RHD virus seeds and adsorbing; adding an incubation agent and performing cell incubation; re-adding a cell maintenance medium and culturing cells to obtain the RHD virus for vaccine preparation; adding an inactivator for inactivation; and then adding a veterinary-pharmaceutically acceptable vaccine adjuvant to obtain a finished product of the RHD vaccine. According to the method, the cell line for virus culture is a mature commercial cell line, the production technology is simple and stable, the operation is easy, the virus content is high, the inter-batch difference is little, the quality is easy to control, and the output and quality of the vaccine can be obviously improved. Through the invention, the produced RHD vaccine has high safety and high immunity, and realizes a complete immune protection effect against the RHD virulent attack.